RESEARCH MONOGRAPH · KDC-MN-015

9-Me-BC

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

62/100

Beta-carboline with surprisingly clean dopaminergic neuroprotection data. Underrated and weird

9-Me-BC (9-methyl-beta-carboline) is one of the stranger compounds in the cognitive-research space, and we mean that affectionately. It's a methylated beta-carboline alkaloid related to harmane and norharmane, but with very different pharmacology because the 9-position methylation seems to flip the compound from neurotoxic in some contexts (the parent beta-carbolines have MAO-inhibitor activity and complicated neurotoxicity profiles) to clearly neuroprotective.

The Polanski group at Saarland did most of the foundational work, particularly on dopaminergic neurons. The 2009 and 2010 papers showed that 9-Me-BC promoted survival and dendritic complexity of midbrain dopaminergic neurons in culture, with effects mediated through upregulation of neurotrophic gene expression (BDNF, GDNF, several others). The MPTP rat model showed protection against dopaminergic cell loss, which is the kind of finding that should have prompted a lot more follow-up work than it actually has.

The Hooks and Bock groups extended this with anti-inflammatory mechanism work, showing modulation of microglial activation states. And there's some interesting work on adult hippocampal neurogenesis stimulation that overlaps thematically with the BDNF story.

Mechanism is partly understood but not pinned down. There's MAO-A inhibition activity (though weaker than the unmethylated parent compounds), gene-expression effects on neurotrophic factors, and possibly direct interaction with several CYP enzymes. The MAO inhibition is the one to watch from a research-safety standpoint because of drug-drug interactions, though at the doses studied in vivo, the effect is modest.

Capsule format vendor sourcing is variable. The synthesis is straightforward chemistry, the methylation step is well-characterized, and HPLC validation should be standard. But the supplier landscape for this compound is much thinner than for the major peptides or even the well-known nootropics, and QC across vendors is uneven. Look for full COAs and ideally mass-spec verification.

Whats holding it back? Probably the obscurity of beta-carboline chemistry to non-specialists, and the lack of a major lab driving sustained research. The compound deserves more attention than it gets.

Interesting tool. Real dopaminergic biology. Worth a serious literature dive.

Evidence: 45
Mechanism: 60
Reliability: 65
Safety: 65
Sourcing: 60
Value: 70
Signal: 68
Staying power: 60

Plain-language summary Intrigue 64 / 100

9-Me-BC (9-methyl-beta-carboline) is a small molecule based on the beta-carboline scaffold. Research suggests it has dopaminergic neuroprotective effects, with potential implications in Parkinson disease research. Capsule format here. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Beta-carboline alkaloid, dopaminergic neuroprotective small molecule (capsule format)

A 182 Da methylated beta-carboline alkaloid characterized for dopaminergic neuroprotective effects, increased dopamine neuron differentiation, and BDNF expression in animal models. Supplied as 30 capsules x 20 mg.

Abstract

9-Methyl-beta-carboline (9-Me-BC; CAS 2521-07-5; molecular formula C12H10N2; molecular weight 182.22) is a small-molecule beta-carboline alkaloid bearing a methyl substituent on the 9-position indole nitrogen. The compound is a member of the broader beta-carboline family, naturally occurring alkaloids found in trace concentrations in many plants (notably the harmal family of psychoactive plants used in traditional preparations) and present at low concentrations in mammalian tissues including human plasma. The synthetic 9-methylated variant has attracted research interest beginning in the 2010s for a distinctive pharmacological profile that combines dopaminergic neuroprotective effects, increased dopamine neuron differentiation in cell culture, and elevated BDNF expression in rodent brain. Unlike many psychoactive beta-carbolines (harmaline, harmine, others), 9-Me-BC has substantially reduced affinity for the monoamine oxidase A enzyme and substantially reduced psychoactive effects at the doses used in published preclinical work. The compound is supplied at Kodiac biolabs as a 30-capsule oral preparation, 20 milligrams per capsule, reflecting the small molecule's stability and good oral bioavailability. There is no FDA-approved IND for 9-Me-BC in any indication. The principal limitations on the strength of the evidence are the relatively short duration of the published research record, dominance of a small number of laboratories (primarily in the German neuroscience research community), and the absence of human clinical data.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-015

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

Acquire 9-Me-BC from the catalog

View 9-Me-BC →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

9-Me-BC

Abstract

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Read the full monograph

Adjacent monographs